Related Experiment Video
Updated: Nov 20, 2025
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Two-year follow-up during fingolimod treatment in a pediatric multiple sclerosis patient still active on first-line
Paolo Immovilli1, Eugenia Rota2, Nicola Morelli3
1Neurology Unit, Guglielmo da Saliceto Civil Hospital, Via Giuseppe Taverna 49, 29121, Piacenza, Italy. Paolo.immovilli.md@gmail.com.
Abstract:
Treatment of pediatric multiple sclerosis (MS) has been increasingly debated in the last few years due to limited knowledge of treatment strategies and therapeutic options. When MS develops at a young age, it usually has a very inflammatory disease course, with many relapses and disease activity as seen in magnetic resonance imaging (MRI). Therefore, treatment with immunomodulatory drugs may be beneficial in these patients. However, limited data are available to date on the treatment of pediatric MS. Although observational, prospective, and retrospective studies provide some information on its treatment course, only one clinical trial in pediatric patients has been published, the PARADIGMS trial, which showed an 82% reduction in relapse rate with fingolimod (0.5 mg/day) versus interferon β-1a (30 μg once weekly intramuscularly). Here, we present the case of a pediatric patient with MS (age of onset, 13 years), who was initially treated with interferon β-1a for 2 years and subsequently switched to fingolimod, owing to clinical and radiological activity despite treatment with interferon β-1a.
Insights
Pediatric multiple sclerosis (MS) treatment is challenging. A case study shows switching from interferon beta-1a to fingolimod improved outcomes for a young MS patient with active disease.
Area of Science:
- Neurology
- Pediatric Neurology
- Immunology
Background:
- Treatment strategies for pediatric multiple sclerosis (MS) are debated due to limited data.
- Pediatric MS often presents with a highly inflammatory disease course, characterized by frequent relapses and MRI-detected activity.
- Immunomodulatory therapies are considered beneficial, but evidence in young patients remains scarce.
Purpose of the Study:
- To present a case study of a pediatric patient with MS.
- To illustrate treatment challenges and therapeutic options in young MS patients.
- To highlight the transition from interferon beta-1a to fingolimod therapy.
Main Methods:
- A case report of a 13-year-old patient diagnosed with MS.
- Initial treatment with interferon beta-1a for two years.
- Subsequent switch to fingolimod due to persistent disease activity.
Main Results:
- The patient experienced clinical and radiological activity despite interferon beta-1a treatment.
- Switching to fingolimod was necessitated by ongoing disease progression.
- This case adds to the limited clinical experience with disease-modifying therapies in pediatric MS.
Conclusions:
- Effective management of pediatric MS requires careful consideration of treatment options.
- Fingolimod may be a viable therapeutic alternative for pediatric MS patients with active disease.
- Further research and clinical trials are crucial to establish optimal treatment protocols for pediatric MS.
More Related Videos
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
06:04Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024